Business Description
Eliem Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US28658R1068
Description
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 306.01 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -13.9 | |||||
| 3-Year EPS without NRI Growth Rate | -9.4 | |||||
| 3-Year FCF Growth Rate | 14.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 91.41 | |||||
| 9-Day RSI | 85.75 | |||||
| 14-Day RSI | 82.3 | |||||
| 6-1 Month Momentum % | 5.66 | |||||
| 12-1 Month Momentum % | -11.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 38.92 | |||||
| Quick Ratio | 38.92 | |||||
| Cash Ratio | 37.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -33.4 | |||||
| Shareholder Yield % | 0.06 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -30.52 | |||||
| ROA % | -29.43 | |||||
| ROIC % | -706.31 | |||||
| ROC (Joel Greenblatt) % | -4815.28 | |||||
| ROCE % | -34.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.95 | |||||
| Price-to-Tangible-Book | 1.97 | |||||
| EV-to-EBIT | -2.24 | |||||
| EV-to-EBITDA | -2.24 | |||||
| EV-to-FCF | -4.39 | |||||
| Price-to-Net-Current-Asset-Value | 1.97 | |||||
| Price-to-Net-Cash | 2.04 | |||||
| Earnings Yield (Greenblatt) % | -44.64 | |||||
| FCF Yield % | -9.82 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers